Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence

Area of Science:

• Endocrinology
• Psychiatry
• Pharmacology

Background:

• Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for managing type 2 diabetes and obesity.
• Concerns have been raised regarding potential associations between GLP-1RA use and suicidality.
• This review synthesizes existing evidence on this critical safety aspect.

Purpose of the Study:

• To conduct the first umbrella review integrating research syntheses on GLP-1RAs and suicidality.
• To provide a comprehensive overview of the current scientific understanding.

Main Methods:

• Systematic search across major scientific databases (MedLine, PubMed, PsychInfo, Web of Science, etc.).
• Inclusion of 12 relevant reviews and meta-analyses from an initial pool of 50 studies.
• Analysis focused on the association between GLP-1RAs and suicidality.

Main Results:

• Consistent findings across most studies indicate no significant association between GLP-1RA use and suicidality.
• GLP-1RAs were associated with improvements in symptomatology, quality of life, and diabetes distress in some studies.
• Potential associations with suicidality were noted in specific contexts, including unrealistic treatment expectations, being underweight, and use of semaglutide and liraglutide.

Conclusions:

• GLP-1RA treatment is considered a safe option for diabetes and obesity management.
• Clinical practice should include careful assessment of patient expectations and suicide risk.
• Proactive risk management is essential to mitigate potential suicidal tendencies.